1）Mihaylova B, et al；Cholesterol Treatment Trialists'（CTT）Collaborators：The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease；Meta-analysis of individual data from 27 randomised trials. Lancet 380：581-590, 2012
2）Cholesterol Treatment Trialists'（CTT）Collaboration：Efficacy and safety of more intensive lowering of LDL cholesterol：A meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet 376：1670-1681, 2010
3）Nordestgaard BG, Varbo A：Triglycerides and cardiovascular disease. Lancet 384：626-635, 2014
4）Iso H, et al；CIRCS Investigators：Fasting and non-fasting triglycerides and risk of ischemic cardiovascular disease in Japanese men and women；The Circulatory Risk in Communities Study（CIRCS）. Atherosclerosis 237：361-368, 2014
5）Sarwar N, et al：Triglycerides and the risk of coronary heart disease；10,158 incident cases among 262,525 participants in 29 Western prospective studies. Circulation 115：450-458, 2007
6）Patel A, et al；Asia Pacific Cohort Studies Collaboration：Serum triglycerides as a risk factor for cardiovascular diseases in the Asia-Pacific region. Circulation 110：2678-2686, 2004
7）Kugiyama K, et al：Remnant lipoprotein levels in fasting serum predict coronary events in patients with coronary artery disease. Circulation 99：2858-2860, 1999
8）McNamara JR, et al：Remnant-like particle（RLP）cholesterol is an independent cardiovascular disease risk factor in women；Results from the Framingham Heart Study. Atherosclerosis 154：229-236, 2001
9）Bezafibrate Infarction Prevention（BIP）study：Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease. Circulation 102：21-27, 2000
10）Keene D, et al：Effect on cardiovascular risk of high density lipoprotein targeted drug treatments niacin, fibrates, and CETP inhibitors；Meta-analysis of randomized controlled trials including 117,411 patients. BMJ 349：g4379, 2014
11）Dyerberg J, et al：Eicosapentaenoic acid and prevention of thrombosis and atherosclerosis? Lancet 2：117-119, 1978
12）Burr ML, et al：Effects of changes in fat, fish, and fibre intakes on death and myocardial reinfarction；Diet and reinfarction trial（DART）. Lancet 2：757-761, 1989
13）GISSI-Prevenzione investigators：Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction；Results of the GISSI-Prevenzione trial. Lancet 354：447-455, 1999
14）Kromhout D, et al；Alpha Omega Trial Group：n-3 fatty acids and cardiovascular events after myocardial infarction. N Engl J Med 363：2015-2026, 2010
15）Bosch J, et al；ORIGIN Trial Investigators：n-3 fatty acids and cardiovascular outcomes in patients with dysglycemia. N Engl J Med 367：309-318, 2012
16）Yokoyama M, et al；Japan EPA lipid intervention study（JELIS）Investigators：Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients（JELIS）；A randomised open-label, blinded endpoint analysis. Lancet 369：1090-1098, 2007
17）Bhatt DL, et al：Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia. N Engl J Med 380：11-22, 2019
18）Manson JE, et al；VITAL Research Group：Marine n-3 fatty acids and prevention of cardiovascular disease and cancer. N Engl J Med 380：23-32, 2019
19）Studer M, et al：Effect of different antilipidemic agents and diets on mortality；A systematic review. Arch Intern Med 165：725-730, 2005
20）2019 ESC/EAS Guidelines for the management of dyslipidaemias；Lipid modification to reduce cardiovascular risk. Atherosclerosis 290：140-205, 2019
21）Budoff M：Effect of icosapent ethyl on progression of coronary atherosclerosis in patients with elevated triglycerides on statin therapy；The EVAPORATE study. American Heart Association Annual Scientific Sessions（AHA 2019）, Philadelphia, PA, November 18, 2019
22）Budoff M, et al：Effect of Vascepa（icosapent ethyl）on progression of coronary atherosclerosis in patients with elevated triglycerides（200-499 mg/dL）on statin therapy；Rationale and design of the EVAPORATE study. Clin Cardiol 41：13-19, 2018
ログイン
ランキング
お知らせ
ログイン
